Last updated: February 27, 2026
What Is the Drug Identified by NDC 75834-0221?
NDC 75834-0221 corresponds to Remdesivir (Veklury), an antiviral medication approved by the FDA for the treatment of COVID-19. Initially Emergency Use Authorized in May 2020, it received full approval in October 2020 for hospitalized patients requiring oxygen or mechanical ventilation.
Market Overview
Current Market Size and Penetration
As of 2023, Remdesivir remains a key antiviral therapy for COVID-19, especially in hospitalized settings. The drug has maintained a significant market share within COVID-19 treatment protocols, with widespread adoption in the U.S., Europe, and select Asian markets.
- Global COVID-19 treatment market (2023): Estimated at approximately US$10 billion, with antivirals like Remdesivir accounting for roughly 65%.
- U.S. market share: Institutional providers and hospitals utilize Remdesivir early in patient treatment, contributing to approximately US$2.5 billion in annual sales.
Competition Landscape
Post-approval, other COVID-19 therapies emerged, including oral antivirals like Paxlovid (Pfizer), molnupiravir (Merck), and monoclonal antibody regimens. These influence Remdesivir's market share due to:
- Ease of administration (oral vs. IV)
- Differing efficacy profiles
- Pricing dynamics
Regulatory Dynamics
Remdesivir continues to be under review for extended indications and use as part of combination therapies. Ongoing studies could expand its label, influencing market size.
Pricing History
Initially, Gilead Sciences set the wholesale acquisition cost (WAC) for Remdesivir at approximately US$520 per vial in 2020. Treatment courses involve six vials, totaling about US$3,120 per patient.
Pricing adjustments over 2021-2023 are minimal, with price revisions influenced by:
- Negotiation with payers
- Government procurements
- Global patent and supply considerations
Pricing Projections (2023-2028)
Assumptions for Price Forecasting
- No significant patent expiry before 2028.
- Continued demand in hospitalized COVID-19 cases.
- Possible reduction in price due to biosimilar or generic manufacturing if regulations change.
- Expansion into prophylactic or outpatient uses remains under clinical trials, potentially affecting pricing structure.
Year-Over-Year Price Trends
| Year |
Estimated Price per Course (USD) |
Notes |
| 2023 |
US$3,120 |
Stable pricing due to supply agreements |
| 2024 |
US$3,060 |
Slight price decrease expected from negotiated discounts |
| 2025 |
US$3,000 |
Potential slight reduction due to increased competition |
| 2026 |
US$2,850 |
Possible entry of generic versions in certain markets |
| 2027 |
US$2,700 |
Generic or biosimilar competition established |
| 2028 |
US$2,550 |
Cost reductions from market saturation |
Market Growth and Revenue Projections
- 2023: Revenue approximates US$2.5 billion
- 2024: Slight decline to US$2.4 billion, factoring in dose reduction and market saturation
- 2025: Stabilizes around US$2.2 billion
- 2026: Decline to US$1.8 billion due to increased biosimilar options
- 2027 and beyond: Further decrease expected, potentially stabilizing around US$1.2 billion as COVID-19 becomes endemic or replaced by vaccines and boosters.
Key Factors Impacting Prices and Market Size
- Patent and exclusivity periods: Patents last until at least 2027, after which biosimilars could enter.
- Regulatory approval for expanded indications: Use in outpatient settings or prophylaxis could increase overall sales volume but pressure prices downward.
- Manufacturing capacity and global supply: Price reductions may occur if supply exceeds demand, especially in emerging markets.
- Competitive therapies: Development of oral antivirals with similar efficacy may lower Remdesivir prices through market competition.
Conclusion
Remdesivir (NDC 75834-0221) occupies a significant role in COVID-19 hospital care, but market share and pricing will decline in the coming years due to biosimilar entry, competition, and potential new indications. Price projections suggest a gradual decrease from current levels, stabilizing around US$2,500–$3,000 per course by 2028.
Key Takeaways
- The drug's current market value is approximately US$2.5 billion annually.
- Prices are expected to decline by approximately 15-20% over the next five years.
- Market share will shrink due to competition from oral antivirals and biosimilars.
- Manufacturers should anticipate increased market pressure post-2027 when patent protections expire.
- Expansion into outpatient use could temporarily stabilize volumes but likely trend prices downward.
FAQs
-
Will Remdesivir’s price decrease further after 2028?
Likely, especially if biosimilar versions gain approval and generic manufacturing begins, increasing supply and reducing prices.
-
Could new formulations or indications impact pricing?
Yes; new indications such as outpatient use or prophylaxis could increase demand temporarily, potentially supporting higher prices initially.
-
How does the competition from oral antivirals influence Remdesivir’s market?
Oral antivirals offer ease of use, which may lead to decreased IV antiviral use, forcing Remdesivir to compete on price and efficacy.
-
What is the potential for biosimilar entry in the U.S.?
Biosimilars could enter post-2027, significantly reducing prices, depending on regulatory and patent landscape.
-
Are there geographic market differences in pricing and availability?
Yes; developing markets may see lower prices due to government interventions and procurement strategies, influencing global pricing trends.
References
[1] Gilead Sciences. (2020). Veklury (Remdesivir) Prescribing Information. Retrieved from https://www.gilead.com
[2] IQVIA. (2023). Pharmaceutical Market Reports.
[3] U.S. Food and Drug Administration. (2020). Remdesivir EUA and approval documentation.
[4] Evaluate Pharma. (2023). Global Sales Forecasts for COVID-19 therapeutics.
